Kedrion Biopharma, commonly referred to as Kedrion, is a leading global player in the biopharmaceutical industry, headquartered in Italy. Founded in 2001, the company has established a strong presence in major operational regions, including Europe and North America, focusing on the development and production of human plasma-derived therapies. Kedrion's core offerings include immunoglobulins, clotting factors, and albumin, which are essential for treating various medical conditions. What sets Kedrion apart is its commitment to quality and innovation, ensuring that its products meet the highest safety standards. With a robust market position, Kedrion has achieved significant milestones, including expanding its product portfolio and enhancing its global distribution network, solidifying its reputation as a trusted provider in the biopharmaceutical sector.
How does Kedrion's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Kedrion's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Kedrion S.p.A. reported total carbon emissions of approximately 27,304,000 kg CO2e. This figure reflects a slight decrease from 2022, when emissions were about 30,122,000 kg CO2e. The emissions data for 2023 does not specify individual Scope 1, 2, or 3 emissions, as these values are not disclosed. However, in 2020, Kedrion reported a total of 6,600 kg CO2e, with Scope 1 emissions at approximately 6,573 kg CO2e and Scope 2 emissions at about 27 kg CO2e. Kedrion's emissions data is cascaded from its parent company, Kedrion Holding Spa, indicating a corporate family relationship. Despite the lack of specific reduction targets or initiatives outlined in their reports, the company is part of a broader industry context that increasingly prioritises sustainability and carbon footprint reduction. As of now, Kedrion has not established any formal science-based targets or specific climate pledges, which may limit their ability to demonstrate a structured approach to emissions reduction. The absence of documented reduction initiatives suggests that further commitment to climate action may be necessary for alignment with industry standards.
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 0,000,000 | 0,000 | - | - | - |
| Scope 2 | - | - | - | - | 00 | - | - | - |
| Scope 3 | - | - | - | - | - | - | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kedrion has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.